HER2 gene amplification and protein expression in pancreatic ductal adenocarcinomas

Applied Immunohistochemistry and Molecular Morphology

Volumn 22, Issue 2, 2014, Pages 146-152

  Aumayr, Klaus ^a   Soleiman, Afschin ^b   Sahora, Klaus ^a   Schindl, Martin ^a   Werba, Gregor ^a   Schoppmann, Sebastian F ^a   Birner, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Pathologie and Zytodiagnostik ^*  (Austria)

Author keywords

amplification; expression; HER2; pancreatic adenocarcinoma

Indexed keywords

ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; DUAL COLOR SILVER IN SITU HYBRIDIZATION; ESOPHAGUS CANCER; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; STOMACH CANCER; TISSUE MICROARRAY; TUMOR CELL;

AGED; CARCINOMA, PANCREATIC DUCTAL; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RECEPTOR, ERBB-2; SILVER; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS;

EID: 84896690925     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31828dc392     Document Type: Article

References (35)

1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
2. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzu-mab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672.
4. Birner P, Oberhuber G, Stani J, et al. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res. 2001;7:1669-1675.
5. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005;353:1652-1654.
6. Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med. 2005;353:1734-1736.
7. Eisenhauer EA. From the molecule to the clinic-inhibiting HER2 to treat breast cancer. N Engl J Med. 2001;344:841-842.
8. Nielsen DL, Andersson M, Kamby C. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev. 2009;35:121-136.
9. Gardmark T, Wester K, De la Torre M, et al. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int. 2005;95:982-986.
10. Bookman MA, Darcy KM, Clarke-Pearson D, et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21: 283-290.
11. Gravalos C, Gomez-Martin C, Rivera F, et al. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clin Transl Oncol. 2011;13:179-184.
12. Konecny GE, Venkatesan N, Yang G, et al. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer. 2008;98:1076-1084.
13. Mendoza N, Phillips GL, Silva J, et al. Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer. Cancer Res. 2002;62:5485-5488.
14. Onn A, Correa AM, Gilcrease M, et al. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res. 2004;10:136-143.
15. Thomas DG, Giordano TJ, Sanders D, et al. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin Cancer Res. 2002;8:788-793.
16. Schoppmann SF, Jesch B, Friedrich J, et al. Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol. 2010;34: 1868-1873.
17. Schoppmann SF, Jesch B, Zacherl J, et al. HER-2 status in primary oesophageal cancer, lymph nodes and distant metastases. Br J Surg. 2011;98:1408-1413.
18. Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-697.
19. Eheman C, Henley SJ, Ballard-Barbash R, et al. Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012;118:2338-2366.
20. Sahmoun AE, D'Agostino RA, Bell RA, et al. International variation in pancreatic cancer mortality for the period 1955-1998. Eur J Epidemiol. 2003;18:801-816.
21. Day JD, Digiuseppe JA, Yeo C, et al. Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol. 1996;27:119-124.
22. Koka V, Potti A, Koch M, et al. Role of immunohistochemical identification of Her-2/neu and detection of variability in over-expression in pancreatic carcinoma. Anticancer Res. 2002;22:1593-1597.
23. Lei S, Appert HE, Nakata B, et al. Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. Int J Pancreatol. 1995;17:15-21.
24. Saxby A, Nielsen A, Scarlett C, et al. Assessment of HER-2 status in pancreatic adenocarcinoma-correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival. Am J Surg Pathol. 2005;29:1125-1134.
25. Tsiambas E, Karameris A, Dervenis C, et al. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis. J Pancreas. 2006;7:283-294.
26. Fedeli F, Boccardo S, Ferro P, et al. Primary pancreatic adenocarcinoma, metastatic lymph node and distant metastasis may differ in HER2 expression, gene amplification and CEP17 copy number: possible implications for diagnostic evaluation and therapy. Mod Pathol. 2011;24:359A.
27. Komoto M, Nakata B, Amano R, et al. HER2 overexpression correlates with survival after curative resection of pancreatic cancer. Cancer Sci. 2009;100:1243-1247.
28. Stoecklein N, Luebke A, Erbersdobler A, et al. Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma. J Clin Oncol. 2004;22:4737-4745.
29. Yamanaka Y, Friess H, Kobrin MS, et al. Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol. 1993;24:1127-1134.
30. Harder J, Ihorst G, Heinemann V, et al. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br J Cancer. 2012;106:1033-1038.
31. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histo-pathology. 2008;52:797-805.
32. Birner P, Schoppmann SF. Her-2 in gastroesophageal cancer: pathobiology, diagnostic and therapeutic implications. Eur Surg. 2011;43:162-167.
33. Sharif S, Ramanathan RK, Potter D, et al. HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma. Digest Dis Sci. 2008;53:3026-3032.
34. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2:897-909.
35. Larbouret C, Gaborit N, Chardes T, et al. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzu-mab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption. Neoplasia. 2012;14: 121-130.